"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 4 | 7 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 2 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 5 | 2 | 7 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 4 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 6 | 4 | 10 |
| 2007 | 9 | 9 | 18 |
| 2008 | 6 | 10 | 16 |
| 2009 | 6 | 6 | 12 |
| 2010 | 6 | 7 | 13 |
| 2011 | 10 | 9 | 19 |
| 2012 | 8 | 4 | 12 |
| 2013 | 8 | 11 | 19 |
| 2014 | 2 | 4 | 6 |
| 2015 | 3 | 5 | 8 |
| 2016 | 8 | 4 | 12 |
| 2017 | 8 | 6 | 14 |
| 2018 | 8 | 11 | 19 |
| 2019 | 13 | 12 | 25 |
| 2020 | 11 | 12 | 23 |
| 2021 | 4 | 19 | 23 |
| 2022 | 0 | 21 | 21 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024 Dec 16; 96(1):68-75.
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
-
Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer. 2024 Jun 04; 32(7):407.
-
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord. 2024 Jul; 87:105672.
-
Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
-
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals. Front Immunol. 2024; 15:1348041.
-
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023 07 05; 29(13):2435-2444.
-
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 04; 29(4):869-879.